Comparing two blood thinners during dialysis for sepsis-related kidney failure
Treatments studied
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two blood-thinning drugs (nafamostat and heparin) that are given during dialysis for kidney failure caused by sepsis. The goal is to see which drug is safer and helps keep the dialysis filter working better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 90 years old.
- You have been diagnosed with sepsis (a severe infection that affects your whole body).
- Your kidneys have failed enough to need a stage 2 or 3 kidney injury (moderate to severe).
- You have been on kidney replacement therapy (dialysis) for at least 24 hours.
- Your doctors expect you to live for at least another 48 hours.
- You do not have active bleeding, chronic kidney disease before this illness, or a known allergy to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to prevent blood clots during kidney dialysis in people with sepsis-related kidney failure. The goal is to see which method is safer and works better to keep the dialysis filter working properly.
This trial tests an experimental drug called nafamostat mesilate to help control blood clotting problems in people with severe infections (sepsis). It aims to reduce the risk of abnormal blood clots that can harm organs.
This trial tests whether a special type of dialysis filter (oXiris) helps reduce blood clotting problems in patients with septic shock and kidney failure. It may offer a better option for those needing kidney support in the ICU.
This trial tests whether a newer, higher-performing dialysis filter helps people with kidney failure and sepsis better than the standard filter. It focuses on patients with high levels of inflammation (measured by a marker called interleukin-6).
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
This trial is testing a medicine called nafamostat mesylate for people with sepsis (a severe infection) that causes blood clotting problems and who are receiving hemofiltration (a type of blood filtering). The goal is to see if this medicine helps improve their recovery.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.